Novo Nordisk shares pop on early-stage weight loss drug trial results
The Danish pharmaceutical giant reported positive early-stage results for its once weekly amycretin obesity drug.
Novo Nordisk next-gen shot shows 22% weight loss in early results
One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their weight in 36 weeks, according to early-stage trial results on Friday, boosting the drugmaker's shares.
Novo Nordisk stock pops on Phase 1 data for new weight loss drug amycretin
Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 products, by mimicking a hormone in the body that provides a satiated feeling and curbs hunger, but adds a different hormone in the pancreas.
An Ozempic alternative shows promising weight loss results — and Novo Nordisk stock surges 12%
Novo Nordisk (NVO) stock jumped 12% in pre-market trading Friday after it released promising results of an early-stage weight loss drug trial.
Novo Nordisk reports 22% weight loss in early subcutaneous amycretin trial
Novo Nordisk on Friday announced early-stage trial results for its amycretin obesity drug for subcutaneous injection, saying people with obesity or overweight treated with the drug achieved a 22% weight loss after 36 weeks.
Novo Nordisk Stock Surges On Weight Loss Drug Data and Analysts Say It's Still a Buy
Novo Nordisk stock is paring its year-over-year deficit on positive early stage trial results for the company's new weight loss drug. Here's what you need to know.
Novo Nordisk leaps on new obesity drug data
Novo Nordisk is currently leading the market for incretin therapies with semaglutide-based products Ozempic for type 2 diabetes and Wegovy for obesity but is coming under competitive pressure from rival therapies from Eli Lilly based on dual GIP/GLP-1 agonist tirzepatide.
Novo Nordisk’s next-generation obesity treatment shows promise in early study
A new weight loss drug from Novo Nordisk helped patients lose a large amount of weight, providing a boost for Novo in the competitive field.
Novo Nordisk spikes as novel obesity drug causes up to 22% of weight loss
Novo Nordisk (NVO) stock gains on promising Phase 1/2 data for the drugmaker's new weight loss drug amycretin. Read more here.
Novo Nordisk amycretin data helps rebut concerns, says BofA
After Novo Nordisk (NVO) reported that subcutaneous amycretin demonstrated up to 22% absolute weight loss at 36-weeks in a Phase 1/2a trial,
Why Nova Nordisk Shares Are Skyrocketing Today?
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/17.OJtTHmzH.js ...
STAT3h
Novo Nordisk is slammed by U.K. trade group for not disclosing payments to health and patient groups
Novo Nordisk was slammed by a U.K. trade group for not disclosing payments to health and patient groups, according to a draft ...
Novo Nordisk Vaults Above LVMH as Europe's Biggest Company
Good news about an experimental weight-loss shot sent shares in Ozempic maker Novo Nordisk soaring, making it once again Europe's most-valuable listed company. A pullback in the Danish drug maker's ...
Novo Nordisk Announces Positive Phase 1b/2a Trial Results For Amycretin In Overweight Or Obesity
Danish healthcare company Novo Nordisk A/S (NVO) announced topline results from a phase 1b/2a clinical trial with amycretin, a ...